PMID- 25684187
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20181020
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 458
IP  - 3
DP  - 2015 Mar 13
TI  - Protection of erythropoietin against ischemic neurovascular unit injuries through 
      the effects of connexin43.
PG  - 656-662
LID - S0006-291X(15)00236-3 [pii]
LID - 10.1016/j.bbrc.2015.02.020 [doi]
AB  - Erythropoietin (EPO) has protective effects on many neurological diseases, 
      including cerebral ischemia. Here, we aimed to test EPO's effects on ischemic 
      neurovascular unit (NVU) injuries and examine whether the effects were dependent 
      on connexin43 (Cx43) mediated gap junctional intercellular communication (GJIC). 
      We detected the expression of Cx43 and phosphorylation of Cx43 (p-Cx43) at 1 d, 3 
      d, and 7 d after middle cerebral artery occlusion (MCAO). Meanwhile, we examined 
      the effects of EPO on NVU injuries including neuronal survival, astrocyte 
      activation and regeneration of endothelial cells as well as whether the effects 
      were Cx43 dependent by using multiple inhibitors. We found EPO highly increased 
      p-Cx43, but not total Cx43 at all chosen times. Importantly, EPO led to 
      neurological and blood-brain barrier functions improvement by associating with 
      promotion of angiogenesis as well as reduction of neuronal death, astrocyte 
      activation and neurotoxic substances levels. Moreover, these effects were 
      significantly weakened by the inhibitors blocking GJIC, Cx43 communicative 
      function, phosphorylation and expression, only Cx43 redistribution inhibitor 
      excluded. Our data suggest the protective effects of EPO on NUV injuries are 
      highly associated with the increase of p-Cx43, which improves GJIC to reduce 
      neurotoxic substances.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Zhou, Ziyi
AU  - Zhou Z
AD  - Department of Neurology, Second Affiliated Hospital, Guangzhou University of 
      Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, 
      Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou 
      510120, China.
FAU - Wei, Xiaobai
AU  - Wei X
AD  - Department of Chinese Integrative Medicine, Huashan Hospital, Fudan University, 
      No.12 Mid. Wulumuqi Road, Shanghai 200040, China.
FAU - Xiang, Jun
AU  - Xiang J
AD  - Laboratory for Neurological Research of the Institute of Chinese Integrative 
      Medicine, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai 
      200032, China.
FAU - Gao, Junpeng
AU  - Gao J
AD  - Department of Chinese Integrative Medicine, Guangzhou First People's Hospital, 
      Guangzhou Medical University, No. 1 Panfu Road, Guangzhou 510180, China.
FAU - Wang, Lixin
AU  - Wang L
AD  - Department of Neurology, Second Affiliated Hospital, Guangzhou University of 
      Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, 
      Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou 
      510120, China.
FAU - You, Jinsong
AU  - You J
AD  - Department of Neurology, Second Affiliated Hospital, Guangzhou University of 
      Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, 
      Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou 
      510120, China.
FAU - Cai, Yefeng
AU  - Cai Y
AD  - Department of Neurology, Second Affiliated Hospital, Guangzhou University of 
      Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, 
      Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou 
      510120, China. Electronic address: caiyefeng@126.com.
FAU - Cai, Dingfang
AU  - Cai D
AD  - Laboratory for Neurological Research of the Institute of Chinese Integrative 
      Medicine, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai 
      200032, China. Electronic address: caidingfang@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150213
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Connexin 43)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (RNA, Small Interfering)
RN  - 11096-26-7 (Erythropoietin)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Calcium/metabolism
MH  - Cell Communication/drug effects
MH  - Connexin 43/analysis/*genetics/metabolism
MH  - Erythropoietin/*therapeutic use
MH  - Gap Junctions/drug effects/genetics/metabolism/pathology
MH  - Gene Expression
MH  - Glutamic Acid/metabolism
MH  - Infarction, Middle Cerebral Artery/*drug therapy/genetics/metabolism/pathology
MH  - Male
MH  - Neurons/drug effects/metabolism/pathology
MH  - Neuroprotective Agents/*therapeutic use
MH  - RNA Interference
MH  - RNA, Small Interfering/genetics
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Cerebral ischemia
OT  - Connexin43
OT  - Erythropoietin
OT  - Gap junctional intercellular communication
OT  - Neurovascular unit
EDAT- 2015/02/17 06:00
MHDA- 2015/05/13 06:00
CRDT- 2015/02/17 06:00
PHST- 2015/01/29 00:00 [received]
PHST- 2015/02/04 00:00 [accepted]
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - S0006-291X(15)00236-3 [pii]
AID - 10.1016/j.bbrc.2015.02.020 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2015 Mar 13;458(3):656-662. doi: 
      10.1016/j.bbrc.2015.02.020. Epub 2015 Feb 13.